Shopping Cart

Your Cart is Empty

Shop Now

Are you over 18?

The Content of this website is for MATURE audiences only.

By continuing to view the website you are claiming that you are 18 years or older.

Welcome to the BMCLA

Our mission is to establish a patient centric approach towards the advancement of the medical cannabis industry in Barbados and the wider region through training, research, and development.

Learn More

Have questions?

Contact our Customer Liaison Officer for help with any of your questions.

Contact Us
/

Conference Agenda

Grounded in Growth ยท November 6โ€“7, 2026

Day 1 โ€” Friday, November 6

Day 1 conference agenda for Friday, November 6, 2026

Day 2 โ€” Saturday, November 7

Day 2 conference agenda for Saturday, November 7, 2026

Select an agenda image to view it at full size.

What are the functions of the BMCLA?

Assist

Where required, assists with the provision of analytical services, also ensures that proper disposal requirements are prescribed for the safe disposal of cannabis which is handled under the Act.

Learn More

Develop

Develop policies, procedures and guidelines to establish the medicinal cannabis industry and to ensure that medicinal cannabis is available to patients in a safe and efficient manner.

Learn More

Provide

Issues licences in relation to the handling of medicinal cannabis in accordance with the provisions of the Act, 2019, also provides for the distribution of educational materials etc.

Learn More

Regulate

Regulates the handling of medicinal cannabis, with the approval of the Barbados Medicinal Cannabis Licensing Board, establishes and maintains an electronic database.

Learn More

Apply Online

Apply online for your License today. If you have an questions, be sure to read our application guidelines and other resources.

Our Latest News & Opportunities

From Our Community

Get the latest top news stories and updates from BMCLA and the Medicinal Cannabis Community. Find videos, articles and downloads on the latest top news stories in the region.

Frequently Asked Questions

Who can be a caregiver?

A patient may designate a person as a caregiver and that person has the responsibility for the immediate care and safety of the patient; to assist the patient with obtaining or using medicinal cannabis or to act in the best interest of the patient. A receiver appointed for a person by the Court, under the Mental Health Act Cap. 45, or where relevant a guardian in accordance with the provisions of the Mental Health Act, shall be deemed to be the caregiver of a person to who the Act applies.

A parent or legal guardian of a patient who is a minor shall be deemed to be the caregiver for that minor, unless that parent or legal guardian designates another person, or a person is designated by an order of the Court.

What is recreational cannabis?

Recreational cannabis primarily uses THC (tetrahydrocannabinol), a psychoactive agent that is responsible for the ‘high’ that comes from the consumption of cannabis via inhalation by smoking/vaping recreationally or oral administration.

I’m a Patient how do I access Medicinal Cannabis?

11. How do you get medicinal cannabis?

A patient can only get access to medicinal cannabis as a prescription by a medical practitioner.

That prescription can only be filled by a pharmacist or authorised personnel in a pharmacy or therapeutic facility.

A pharmacist or authorised personnel in a pharmacy shall only dispense or supply medicinal cannabis on the submission by a patient or where applicable, a caregiver, of a prescription and a valid form of identification.

Upon dispensing medicinal cannabis to a patient (or, where applicable, a caregiver), a pharmacist or authorised personnel shall ensure that the label given in respect of the prescription has the information required by Pharmacy (Compounding and Dispensing of Drugs and Poisons) Regulations, 1986.

A pharmacist shall enter the information in a register kept by him/her and established for that purpose, in the prescribed manner.

A person who consumes medicinal cannabis without being authorised to use medicinal cannabis by a prescription or recommendation from a medical practitioner is guilty of an offence and is liable on conviction on indictment to a fine of $100 000 or to imprisonment for a term of 10 years or to both.

12. How is medicinal cannabis administered?

Medical cannabis can be administered by a variety of formulations which may include vapours, tinctures, oromucosal sprays, oral forms, transdermal patches, ointments and suppositories.

13. Will there be rigorous testing done to medicinal cannabis?

The BMCLA in conjunction with accredited testing laboratories will facilitate the testing of medicinal cannabis to ensure the products meet safety and efficacy requirements.

14. Will there be clear guidelines for prescribing medicinal cannabis for the use of patients or will doctors be left to experiment?

The BMCLA and its Board, are responsible for regulating the medicinal cannabis industry, through the formulation and implementation of appropriate policies, procedures and guidelines, as well as establishing the code of practice for practitioners in the industry. We work closely with the Ministry of Health and Wellness via its regulatory bodies such as the Barbados Drug Service to ensure safe and evidence-based treatment options for patients. Currently, there are five legally-approved medicinal cannabis drugs, placed on the National Drug Formulary. Patients can access these drugs under the provisions of Section 12 of the Drug Abuse (Prevention and Control) Act Cap 131.

15. Are there dose limitations?

In circumstances where a prescription by a medical practitioner requires repeated usage over a period of 3 months, a pharmacy or therapeutic facility shall not dispense to that patient more than 30-day supply of individual does at a time.

What is Medicinal Cannabis?

Medicinal Cannabis is cannabis that is grown and sold pursuant to the Medicinal Cannabis Industry Act, 2019 that includes the seeds, immature plants as well as all parts of the plant, along with resin extracted from any part of the plant, every compound, manufacture, salt, derivative, mixture or preparation from cannabis; or cannabis concentrate; that is cultivated, processed, manufactured, distributed or sold under a licence from the BMCLA. As a medicine, it is prescribed and recommended by physicians to provide a therapeutic effect.

Why is smoking cannabis for medical purposes not permitted?

There are two major concerns regarding smoking medicinal cannabis.

Firstly, smoking is a particularly harmful way of taking medicinal cannabis, mainly because it poses comparable risks for bronchitis and lung cancer, as is the smoking of cigarettes. Smoking medicinal cannabis is not permitted by local or international Health authorities.

Secondly, approved medicines used in Barbados are produced under strict conditions to ensure efficacy and safety. It is important that medical doctors know that medicines have been tested and are standardized by dose and therapeutic response. This means doctors can monitor the effects of the drug and doses can be adjusted according to a patient’s needs.

It is understood that smoked cannabis will not be prescribed in Barbados because smoked plant products will not satisfy governmental requirements.

What are the long-term effects of cannabis use?

Using cannabis frequently (daily or almost daily) and over a long time (several months or years) can[1]:

  • Hurt your lungs and make it harder to breathe, if smoked
  • Cannabis smoke may contain many of the same harmful chemicals found in tobacco smoke
  • Affect your mental health
  • Frequent use of THC based products over a long time increases the risk of cannabis dependence
  • Increased risk of developing psychotic disorders
  • Early exposure of cannabis use during the adolescent years can impair brain development and functioning
  • Increased risk of cardiovascular disease

[1] Weinstein, AM, Cohen, K. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review from Public Health Prospective. Frontiers in Public Health 2018; 6:1-8. doi: 10.3389/fpubh.2018.00162.